Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RXRX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| HDAC Inhibitor REC-2282 | Neurofibromatosis Type 2 | Phase 2/3 · NCT05130866 | Terminated |
| CDK7 Inhibitor GTAEXS617 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1/2 · NCT05985655 | Recruiting |
| RBM39 Degrader REC-1245 | Unresectable | Phase 1/2 · NCT06678659 | Recruiting |
| REC-3964 | Recurrent Clostridioides Difficile Infection | Phase 2 · NCT06536465 | Terminated |
| MEK Inhibitor REC-4881 | Familial Adenomatous Polyposis | Phase 1/2 · NCT05552755 | Recruiting |
| REC-7735 | Solid Tumors | Phase 1/2 · NCT07819136 | Recruiting |
| REC-994 | Cerebral Cavernous Malformation | Phase 2 · NCT05085561 | Completed |
| SOC | Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1/2 · NCT05985655 | Recruiting |
| EXS73565 | Relapsed or Refractory B-cell Malignancies | Phase 1 · NCT06980116 | Recruiting |
| LSD1 Inhibitor EXS74539 | Solid Tumor | Phase 1 · NCT07517198 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RXRX holds $549.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $91.7M/quarter from operations, an estimated runway of 18 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 33 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RXRX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| ARK Investment Management LLC | Institution (13G, 5%+) | 44,745,024 | 7.18% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 44,541,605 | 7.15% | 2026-06-30 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 31,369,274 | 5.04% | 2026-06-30 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 30,001,137 | 4.82% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 26,744,129 | 4.29% | 2026-06-30 |
| Blake Borgeson Director |
Insider | 6,068,287 | 0.97% | 2026-11-03 |
| Dean Y Li Director |
Insider | 3,319,755 | 0.53% | 2026-10-01 |
| Najat Khan CEO and President, Director |
Insider | 2,072,890 | 0.33% | 2026-09-08 |
| Ben R Taylor Chief Financial Officer |
Insider | 1,071,462 | 0.17% | 2026-09-15 |
| David Hallett Chief Scientific Officer |
Insider | 1,043,837 | 0.17% | 2026-08-17 |
| Christopher Gibson Director · +2.87M options |
Insider | 883,735 | 0.14% | 2026-06-05 |
| Zavain Dar Director |
Insider | 245,371 | 0.04% | 2026-10-01 |
Share count 622,759,259 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RXRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →